Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Journal of Pediatric Gastroenterology and Nutrition|April 20, 2022
Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel DiseaseLina Yossef, Molly Wright, Jason Benedict, et al.
The American Journal of Managed Care|October 27, 2025
The biosimilar shift: trending infliximab biosimilar utilization and associated cost savings for commercial insuranceSamantha R Paglinco, Mahmoud Abdel-Rasoul, Megan McNicol, et al.
JPGN Reports|August 15, 2025
The Transition Care Index: Standardizing comprehensive transition and transfer for young adults with inflammatory bowel diseaseHilary K Michel, Jennifer L Dotson, Jennie G David, et al.
Journal of Pediatric Gastroenterology and Nutrition|February 9, 2024
Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel diseaseMegan McNicol, Mahmoud Abdel-Rasoul, Madeline G McClinchie, et al.
JPGN Reports|November 17, 2025
Variability of esophageal food impaction management across pediatric specialtiesRaul E Sanchez, Sabine Eid, Julie Luna-Torres, et al.
Pediatric Rheumatology Online Journal|September 11, 2017
Assessment of transition readiness in adolescents and young adults with chronic health conditionsPaul T Jensen, Gabrielle V Paul, Stephanie LaCount, et al.
Inflammatory Bowel Diseases|September 25, 2021
The Pediatric Inflammatory Bowel Disease Medical Home: A Proposed ModelHilary K Michel, Brendan Boyle, Jennie David, et al.
Clinical Pharmacology and Therapeutics|December 23, 2020
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's DiseaseYe Xiong, Tomoyuki Mizuno, Ruben Colman, et al.
Pediatric Quality & Safety|June 29, 2022
Improving Hepatitis B Vaccination Rates among At-risk Children and Adolescents with Inflammatory Bowel DiseaseMegan Megan McNicol, Amy Donegan, Kate Hawa, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's diseaseRuben J Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Pageof 7